Menu
Shedding Light on the Risks
& Benefits of Medications
Shedding Light on the Risks
& Benefits of Medications FDA Drug Recalls and Warnings: Serious Risks of Unapproved Botox Injectables
Get the latest FDA updates on medication recalls, manufacturing violations, and quality concerns that could affect your prescriptions
December 10, 2025
0 Comments
republishon this page:
Welcome to the FDA Recalls and Warnings Update, a series dedicated to keeping you informed about the latest medication recalls, manufacturing violations, and quality concerns affecting your prescriptions. In this installment, we’re highlighting warning letters sent to 18 companies for selling “unapproved and misbranded” botulinum toxin injectable drugs (“Botox” products) over the internet.
Botulinum toxin injectable drugs work by temporarily blocking nerve activity in muscles, reducing muscle movement. The injections are used to temporarily improve the appearance of facial wrinkles as well as to treat medical conditions such as chronic migraines, excessive sweating (hyperhidrosis), muscle stiffness, and urinary incontinence. FDA-approved brand-name botulinum toxin products include Botox, Botox Cosmetic, Daxxify, Myobloc, and Xeomin.
The FDA announced the warning letters in a news release posted November 5, 2025, stating that the unapproved products have been associated with serious health risks, including botulism symptoms. FDA-approved botulinum toxin drugs are prescription-only and carry a boxed warning, which is the most serious kind of safety warning, about the risk of toxin effects spreading to distant parts of the body from the injection site. The FDA advises that if you have symptoms of botulism, including trouble swallowing or breathing after receiving a botulinum toxin product injection, you should seek immediate medical care.
Many of the websites receiving warning letters sell their products internationally and feature Korean aesthetic products, including Korean-made “dermal fillers.” Injectable dermal fillers are promoted as a treatment for improving the appearance of wrinkles. Some of the sites advise that injectables should be administered by a trained health professional. However, no prescription or special credentials are required to make a purchase.
How to Read This Report
This report is prepared using the most recent information posted in the FDA’s Enforcement Reports Database (for recalls), Warning Letters Database (for warning letters), and Drug Imports Alerts Database (for drug importers subject to import bans). Not all new entries to the databases are included in this report. Selected entries are chosen based on the type of product and the potential safety impact of the recall or warning.
Recall announcements and warnings are simplified to improve clarity and accessibility. In some cases, additional sources such as company statements, FDA press releases, and industry publications may provide further details. The primary sources for this report include:
Recalls (Enforcement Reports Database)
The Food and Drug Administration (FDA) categorizes product recalls in its Enforcement Report database based on the level of health risk, labeling them as Class I, II, III, or “not yet classified.”
While the database includes drugs, food, cosmetics, medical devices, biologics, tobacco, and veterinary products, this report only covers selected drug recalls.
- Class I recalls are the most serious. In these situations, there is “reasonable probability that the use of or exposure to a product will cause serious adverse health consequences or death.”
- Class II recalls are for drugs that may cause temporary or medically reversible adverse health consequences or where use of the product is unlikely to result in serious adverse health consequences.
- Class III recalls are the least serious. Use of the product is not likely to cause adverse health consequences.
Warning Letters (Warning Letters Database)
Drug manufacturers, supplement companies, and medical device makers may receive a Warning Letter from the FDA if they commit serious violations of federal regulations. This letter comes from an overseeing FDA office, such as the Center for Drug Evaluation and Research. Common violations include poor manufacturing practices, false product claims, selling misbranded items, or marketing unapproved products. The letter gives the recipient a chance to correct the issues and requires a response, usually within 15 working days. If the recipient does not believe that they are in violation of FDA regulations, they may reply with an explanation of their reasoning.
In most cases, company responses to FDA warning letters are not made public. If the FDA verifies that a corrective action has been taken, it may issue a “close-out” letter. If a violation is not correctable or is not verified by the FDA, no close-out letter will be issued. Individuals interested in finding out the status of a warning letter may submit an FDA Freedom of Information Act Request.
Drug Imports Alerts Database
FDA Import Alerts notify field staff and the public when the agency has enough evidence to detain products without physical examination (DWPE) due to suspected violations of FDA laws, including violations of “current good manufacturing practices for finished pharmaceuticals” or unapproved new drugs. The violation lists are arranged by type of violation, then by country and then by the importing company. In some cases, Import Alerts may be linked to Warning Letters for issues like manufacturing violations.
FDA Warning Letters: Online Sales of Unapproved and Misbranded Drugs over the Internet
Company: Dermax Company, Ltd.
Location: China
Store Website: https://dermaxshop.com
Warning Letter Date: November 3, 2025
FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)
Types of Products Sold: Injectable botulinum toxin products for cosmetic and medical uses
Type of Warning: Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet
FDA Warning: The website sells drug products that have not been FDA-approved. Because the product labels do not include adequate directions for safe and FDA-intended use, the products are considered to be “misbranded” under FDA regulations. This poses an inherent risk for consumers because the drugs do not carry the same assurances of safety and effectiveness as drugs subject to FDA oversight. What’s more, injectable drugs are particularly hazardous. By bypassing the body’s natural barriers, they give toxic ingredients or microbial contaminants direct access to the bloodstream, raising the risk of severe infection and life-threatening sepsis.
Required Actions: The website must cease selling unapproved and misbranded drugs. The company should review its websites, product labels, and promotional materials to ensure that it is not violating FDA regulations for any of its products offered for sale, not just the products specified in the warning letter.
Within 15 days, the company must respond in writing to the FDA with a description of how it has addressed the violations. Alternatively, they must respond with an explanation, with supporting materials, if they do not believe they have violated regulations.
Potential Consequences: Failure to address the violations may result in legal action, including product seizure or an injunction. For non-U.S. companies, products that appear to be misbranded or unapproved new drugs may be detained or refused admission.
Link: FDA Warning Letter
Read the warning letters for a complete description of violations.
Additional FDA Warning Letters
The following companies with websites selling unapproved and misbranded botulinum toxin products received similar FDA warning letters on November 3, 2025. The company name links to the FDA warning letter.
Consumers should always verify that an online website selling medications is a licensed pharmacy. The FDA’s “Be Safe Rx” page has advice on buying from an online pharmacy.
AceCosm (acecosm.com)
Aesthetic Essentials Limited (aesthetic-essentials.com)
CelestaPro (celestapro.com)
Cosmenic (cosmenic.net)
COSMO KOREA (cosmo-korea.com)
Derma Solution (derma-solution.com)
Dermacare dba Filler Outlet (filleroutlet.com)
Dermax Co., Ltd (dermaxshop.com)
Elle Pharm (ellepharm.com)
Estaderma (estaderma.com)
Glam Derma (glamderma.com)
Glow Nest Beauty (glownestbeauty.com)
Glowface (glowface.store)
Korean Aesthetic dba Korean Fillers (koreafillerexperts.com)
Korean Aesthetic dba Korean Fillers (koreanfillers.com)
Maypharm (maypharm.net)
Meamo (meamoshop.com)
MJS Medicals (mjsmedicals.com)
Want to Share Your Story?
If you’ve experienced side effects or medication issues related to this topic, we want to hear from you.
Submit Your Story- Office of the Commissioner. (2025, November 5). FDA warns companies over illegal marketing of botox and related products. U.S. Food And Drug Administration.
- National Library of Medicine. (n.d.). Botox. Botulinum Toxin | Botox Injections | MedlinePlus.
- Research, C. F. D. E. A. (2022, November 22). BeSafeRX: Resources for Consumers. U.S. Food And Drug Administration.
DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.
While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual’s medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.
on this page:
RECOMMENDED:
DONATE:
Help fund our fight for improved medication safety and transparency by supporting our independent journalism.
Give NowWe seek to create a world where there are safer medications for all and where all people are fully informed about their medication benefits and side effects, using our explanatory and investigative journalism to both inform and stimulate public discussion to drive toward solutions.
Republish This Story for Free
Creative Commons License (CC BY-NC-ND 4.0)MedShadow.org is dedicated to empowering people with our evidence-based journalism about the safest ways to take over-the-counter (OTC) and prescription (Rx) medications.
We also seek to stimulate public discussion about potential improvements to drug research, manufacturing and distribution processes. and also to encourage the improvement of processes to ensure that we are all better protected.
As a result, we encourage other nonprofit newsrooms, mission-aligned outlets, and advocacy organizations to republish our original content under the following conditions:
You May Republish Our Articles for Free If:
1. We Are Credited Fully and Clearly
You must include the byline and credit MedShadow.org as the original publisher. Please include a link to the original article at the top or bottom of the piece. Use the following attribution:
This article was originally published by MedShadow, a nonprofit foundation that focuses on the safest ways to take over-the-counter and prescription medications.
2. Our Content Isn’t Edited Without Permission
You may make small changes for clarity, such as adjusting headlines, subheadings, or transitions, but you may not change the core meaning, tone, or intent of the article. For substantive edits, email us at republish@medshadow.org for review and approval.
3. You Do Not Sell Or Use Our Content Commercially
Our work is free to share, but it may not be sold, monetized, or repurposed for commercial gain. You may not republish our articles behind a paywall or in publications whose primary purpose is advertising or product promotion. You may not place drug or supplement advertising adjacent to our story.
4. Photos, Graphics, and Multimedia Are Not Used Without Permission
Only the text of the article is available for republication. Images, graphics, and videos may not be reused without explicit written permission, unless they are clearly marked as Creative Commons licensed. Contact us if you’d like to request reuse of a visual asset.
You May Not:
- Use our content to promote a product, service, or political candidate
- Republish only part of an article or create derivative works without permission
- Add affiliate links, advertising overlays, or lead generators
- Translate the article without written permission
Contact Us
If you’re unsure whether your intended use falls within these guidelines, or would like to discuss a formal syndication or licensing arrangement, please email: republish@medshadow.org
We want our journalism to reach as many people as possible, especially those making critical decisions about medications and health.
Article HTML
<!-- wp:paragraph -->
<p>Welcome to the FDA Recalls and Warnings Update, a series dedicated to keeping you informed about the latest medication recalls, manufacturing violations, and quality concerns affecting your prescriptions. In this installment, we’re highlighting warning letters sent to 18 companies for selling “unapproved and misbranded” botulinum toxin injectable drugs (“Botox” products) over the internet.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><a href="https://medlineplus.gov/botox.html" target="_blank" rel="noreferrer noopener">Botulinum toxin</a> injectable drugs work by temporarily blocking nerve activity in muscles, reducing muscle movement. The injections are used to temporarily improve the appearance of facial wrinkles as well as to treat medical conditions such as chronic migraines, excessive sweating (hyperhidrosis), muscle stiffness, and urinary incontinence. FDA-approved brand-name botulinum toxin products include Botox, Botox Cosmetic, Daxxify, Myobloc, and Xeomin.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The FDA announced the warning letters in a <a href="https://www.fda.gov/news-events/press-announcements/fda-warns-companies-over-illegal-marketing-botox-and-related-products" target="_blank" rel="noreferrer noopener">news release</a> posted November 5, 2025, stating that the unapproved products have been associated with serious health risks, including botulism symptoms. FDA-approved botulinum toxin drugs are prescription-only and carry a boxed warning, which is the most serious kind of safety warning, about the risk of <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485d9b71-6881-42c5-a620-a4360c7192ab" target="_blank" rel="noreferrer noopener">toxin effects</a> spreading to distant parts of the body from the injection site. The FDA advises that if you have symptoms of botulism, including trouble swallowing or breathing after receiving a botulinum toxin product injection, you should seek immediate medical care.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>Many of the websites receiving warning letters sell their products internationally and feature Korean aesthetic products, including Korean-made “dermal fillers.” Injectable dermal fillers are promoted as a treatment for improving the appearance of wrinkles. Some of the sites advise that injectables should be administered by a trained health professional. However, no prescription or special credentials are required to make a purchase.</p>
<!-- /wp:paragraph --><!-- wp:lightweight-accordion/lightweight-accordion {"title":"How to Read This Report"} -->
<!-- wp:paragraph -->
<p>This report is prepared using the most recent information posted in the <a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm" target="_blank" rel="noreferrer noopener">FDA’s Enforcement Reports Database</a> (for recalls), <a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters" target="_blank" rel="noreferrer noopener">Warning Letters Database</a> (for warning letters), and<a href="https://www.fda.gov/industry/actions-enforcement/import-alerts" target="_blank" rel="noreferrer noopener"> Drug Imports Alerts Database</a> (for drug importers subject to import bans). Not all new entries to the databases are included in this report. Selected entries are chosen based on the type of product and the potential safety impact of the recall or warning.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>Recall announcements and warnings are simplified to improve clarity and accessibility. In some cases, additional sources such as company statements, FDA press releases, and industry publications may provide further details. The primary sources for this report include:</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Recalls (Enforcement Reports Database)</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p>The Food and Drug Administration (FDA) categorizes product recalls in its Enforcement Report database based on the level of health risk, labeling them as Class I, II, III, or “not yet classified.”</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>While the database includes drugs, food, cosmetics, medical devices, biologics, tobacco, and veterinary products, this report only covers selected drug recalls.</p>
<!-- /wp:paragraph --><!-- wp:list -->
<ul class="wp-block-list"><!-- wp:list-item -->
<li>Class I recalls are the most serious. In these situations, there is “reasonable probability that the use of or exposure to a product will cause serious adverse health consequences or death.”</li>
<!-- /wp:list-item --><!-- wp:list-item -->
<li>Class II recalls are for drugs that may cause temporary or medically reversible adverse health consequences or where use of the product is unlikely to result in serious adverse health consequences.</li>
<!-- /wp:list-item --><!-- wp:list-item -->
<li>Class III recalls are the least serious. Use of the product is not likely to cause adverse health consequences.</li>
<!-- /wp:list-item --></ul>
<!-- /wp:list --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Warning Letters (Warning Letters Database)</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p>Drug manufacturers, supplement companies, and medical device makers may receive a Warning Letter from the FDA if they commit serious violations of federal regulations. This letter comes from an overseeing FDA office, such as the Center for Drug Evaluation and Research. Common violations include poor manufacturing practices, false product claims, selling misbranded items, or marketing unapproved products. The letter gives the recipient a chance to correct the issues and requires a response, usually within 15 working days. If the recipient does not believe that they are in violation of FDA regulations, they may reply with an explanation of their reasoning.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>In most cases, company responses to FDA warning letters are not made public. If the FDA verifies that a corrective action has been taken, it may issue a “<a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/about-warning-and-close-out-letters" target="_blank" rel="noreferrer noopener">close-out</a>” letter. If a violation is not correctable or is not verified by the FDA, no close-out letter will be issued. Individuals interested in finding out the status of a warning letter may submit an <a href="https://www.fda.gov/regulatory-information/freedom-information/how-make-foia-request" target="_blank" rel="noreferrer noopener">FDA Freedom of Information Act Request</a>.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Drug Imports Alerts Database</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p>FDA Import Alerts notify field staff and the public when the agency has enough evidence to detain products without physical examination (DWPE) due to suspected violations of <a href="https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211" target="_blank" rel="noreferrer noopener">FDA laws</a>, including violations of “current good manufacturing practices for finished pharmaceuticals” or <a href="https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-99" target="_blank" rel="noreferrer noopener">unapproved new drugs</a>. The violation lists are arranged by type of violation, then by country and then by the importing company. In some cases, Import Alerts may be linked to Warning Letters for issues like manufacturing violations.</p>
<!-- /wp:paragraph -->
<!-- /wp:lightweight-accordion/lightweight-accordion --><!-- wp:heading -->
<h2 class="wp-block-heading">FDA Warning Letters: Online Sales of Unapproved and Misbranded Drugs over the Internet</h2>
<!-- /wp:heading --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Company: Dermax Company, Ltd.</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Location</strong>: China<br><strong>Store Website</strong>: https://dermaxshop.com<br><strong>Warning Letter Date</strong>: November 3, 2025<br><strong>FDA Department Issuing Warning</strong>: Center for Drug Evaluation and Research (CDER)<br><strong>Types of Products Sold</strong>: Injectable botulinum toxin products for cosmetic and medical uses<br><strong>Type of Warning</strong>: Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet<br><strong>FDA Warning</strong>: The website sells drug products that have not been FDA-approved. Because the product labels do not include adequate directions for safe and FDA-intended use, the products are considered to be “misbranded” under FDA regulations. This poses an inherent risk for consumers because the drugs do not carry the same assurances of safety and effectiveness as drugs subject to FDA oversight. What’s more, injectable drugs are particularly hazardous. By bypassing the body’s natural barriers, they give toxic ingredients or microbial contaminants direct access to the bloodstream, raising the risk of severe infection and life-threatening sepsis.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Required Actions</strong>: The website must cease selling unapproved and misbranded drugs. The company should review its websites, product labels, and promotional materials to ensure that it is not violating FDA regulations for any of its products offered for sale, not just the products specified in the warning letter.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>Within 15 days, the company must respond in writing to the FDA with a description of how it has addressed the violations. Alternatively, they must respond with an explanation, with supporting materials, if they do not believe they have violated regulations.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Potential Consequences</strong>: Failure to address the violations may result in legal action, including product seizure or an injunction. For non-U.S. companies, products that appear to be misbranded or unapproved new drugs may be detained or refused admission.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Link</strong>:<a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dermax-co-ltd-718712-11032025" target="_blank" rel="noreferrer noopener"> FDA Warning Letter<br></a>Read the warning letters for a complete description of violations.</p>
<!-- /wp:paragraph --><!-- wp:embed {"url":"https://www.tiktok.com/@medshadow_org/video/7584939939112963358?lang=en","type":"video","providerNameSlug":"tiktok","responsive":true} -->
<figure class="wp-block-embed is-type-video is-provider-tiktok wp-block-embed-tiktok"><div class="wp-block-embed__wrapper">
https://www.tiktok.com/@medshadow_org/video/7584939939112963358?lang=en
</div></figure>
<!-- /wp:embed --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Additional FDA Warning Letters</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p>The following companies with websites selling unapproved and misbranded botulinum toxin products received similar FDA warning letters on November 3, 2025. The company name links to the FDA warning letter.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>Consumers should always verify that an online website selling medications is a licensed pharmacy. The FDA’s “<a href="https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/besaferx-resources-consumers" target="_blank" rel="noreferrer noopener">Be Safe Rx</a>” page has advice on buying from an online pharmacy.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/acecosm-718610-11032025" target="_blank" rel="noreferrer noopener">AceCosm</a> (acecosm.com)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aesthetic-essentials-limited-718707-11032025" target="_blank" rel="noreferrer noopener">Aesthetic Essentials Limited</a> (aesthetic-essentials.com)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/celestapro-718613-11032025" target="_blank" rel="noreferrer noopener">CelestaPro</a> (celestapro.com)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cosmenic-718621-11032025" target="_blank" rel="noreferrer noopener">Cosmenic</a> (cosmenic.net)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cosmo-korea-11032025" target="_blank" rel="noreferrer noopener">COSMO KOREA</a> (cosmo-korea.com)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/derma-solution-11032025" target="_blank" rel="noreferrer noopener">Derma Solution</a> (derma-solution.com)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dermacare-dba-filler-outlet-718715-11032025" target="_blank" rel="noreferrer noopener">Dermacare dba Filler Outlet</a> (filleroutlet.com)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dermax-co-ltd-718712-11032025" target="_blank" rel="noreferrer noopener">Dermax Co., Ltd</a> (dermaxshop.com)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/elle-pharm-718713-11032025" target="_blank" rel="noreferrer noopener">Elle Pharm</a> (ellepharm.com)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/estaderma-718714-11032025" target="_blank" rel="noreferrer noopener">Estaderma</a> (estaderma.com)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glam-derma-11032025" target="_blank" rel="noreferrer noopener">Glam Derma </a>(glamderma.com)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glow-nest-beauty-718710-11032025" target="_blank" rel="noreferrer noopener">Glow Nest Beauty</a> (glownestbeauty.com)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glowface-11032025" target="_blank" rel="noreferrer noopener">Glowface</a> (glowface.store)<br>Korean Aesthetic dba Korean Fillers (koreafillerexperts.com)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/korean-aesthetic-dba-korean-fillers-718842-11032025-0" target="_blank" rel="noreferrer noopener">Korean Aesthetic dba Korean Fillers</a> (koreanfillers.com)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/maypharm-718717-11032025" target="_blank" rel="noreferrer noopener">Maypharm</a> (maypharm.net)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/meamo-11032025" target="_blank" rel="noreferrer noopener">Meamo</a> (meamoshop.com)<br><a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mjs-medicals-11032025" target="_blank" rel="noreferrer noopener">MJS Medicals</a> (mjsmedicals.com)</p>
<!-- /wp:paragraph -->